Board of directors



Anders Lundberg

Chairman of the Board (member of the board since 2017)

About: M.Sc. Mechanical Engineering, KTH, Stockholm, Sweden. Founder and CEO of a telecom equipment supplier recognized by the market and later brought to a successful IPO in 2011 on the MID-CAP list OMX-Nasdaq [TRMO:Transmode]

Other assignments:
AJ Lundberg Kapitalförvaltning AB;Board member
Modern Car Group International AB ;Board member 
Sollentunafastigheter 2 AB; Deputy board member 
Sollentunahem AB; Deputy board member

Holdings in the Company: Via AJ Lundberg Kapitalförvaltning AB 296 509 shares, 67259 warrants T0 1 and 0 warrants 2020/2023B

Independent in relation to Prostatype Genomics, its senior management and major shareholders.

Dr. Michael Häggman

Board Member since 2018

About: M.D, Ph.D. associate professor, department of Urology, Akademiska University Hospital, Uppsala, Sweden. More than 30 years of experience practicing as urologist with an extensive national and international network among urologists.

Other assignments: General partner in Skrotum Kommanditbolag and deputy member of the board of Kardinaltalet AB.

Holdings in the Company: 14817 shares, 5767 warrants T0 1 and 0 warrants 2020/2023B

Independent in relation to Prostatype Genomics, its senior management and major shareholders.

Karlheinz Schmelig

Board Member since 2013

About: BSc in Business Administration, DHBW Mannheim, Germany. MBA, Kelley School of Business, Bloomington, USA. Managing Director (Geschäftsführer) of Creathor Venture Management GmbH, Bad Homburg (advisor to Creathor Funds).

Other assignments:
Biofrontera AG, Leverkusen, Germany; Supervisory Board Member
Phenex Pharmaceuticals, Heidelberg, Germany;  Supervisory Board Member
CryoTherapeutics SA, Awans, Belgium; Supervisory Board Member,
Cevec Pharmaceuticals, Cologne, Germany; Board Member
Tacalyx GmbH, Berlin, Germany; Board Member
Acousia Therapeutics GmbH, Tübingen, Germany. Board Observer

Holdings in the Company: Representing Creathor Ventures, 3 079 911 shares, 443561 warrants TO 1 and 0 warrants 2020/2023B. Personal holding: 9951 shares, 1341 TO1.

Independent in relation to Prostatype Genomics and its senior management.  Dependent in relation to major shareholders.

Håkan Englund

Board Member since 2019

About: Various courses in economics and chemistry from Uppsala University, Sweden. Courses in polymer technology at Royal Institute of Technology in Stockholm, Sweden. CEO and owner, JDS Invest. More than 30 years of operational and investment experience from life science and health care industry with focus on commercialization and business development. Håkan has held several leading management positions at Pharmacia Biotech and Phadia and has during his career developed extensive national and international relevant networks.

Other assignments:
Antrad Medical AB; Board member
BioArctic AB; Board member
GlycoBond AB; Deputy board member
SecureAppbox AB;Chairman of the Board
Ultimovacs ASA ; Deputy board member ( Ending April 2022)

Holdings in the Company: Via JDS Invest AB 707605 shares, 276655 warrants T0 1 and 0 warrants 2020/2023B

Independent in relation to Prostatype Genomics, its senior management and major shareholders.

Mattias Prage

Board Member since 2022

About: Lawyer and partner at Advokatfirman Lindahl, specialized in corporate law, financing and commercial contracts.

Holdings in the Company: None (independent board member)

Independent in relation to Prostatype Genomics, its senior management and major shareholders.